Diagnostic biomarkers, such as commonly studied mesothelin and fibulin, could allow an earlier diagnosis of MM and, therefore, enable detection of the disease in earlier stages, leading to a better prognosis [7,8,9,10]. This evidence concerns the gene MSLN and Miyoshi myopathy.